LobbyingLeavitt Partners, LLC on Behalf of Sickle Cell Disease Partnership lobbying by quarter
Leavitt Partners, LLC on Behalf of Sickle Cell Disease Partnership's latest lobbying report covers Q2 2026, at $20K. The four quarters Q4 2025–Q3 2026 total $60K. Its first report covers Q3 2023; the issues it reports most are Health Issues.
Leavitt Partners, LLC on Behalf of Sickle Cell Disease Partnership
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $60K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q3 2023
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q3 2023 | $40K | 1 |
| Q4 2023 | $20K | 1 |
| Q1 2024 | $20K | 1 |
| Q2 2024 | $20K | 1 |
| Q3 2024 | $20K | 1 |
| Q4 2024 | $20K | 1 |
| Q1 2025 | $20K | 1 |
| Q2 2025 | $20K | 1 |
| Q3 2025 | $20K | 1 |
| Q4 2025 | $20K | 1 |
| Q1 2026 | $20K | 1 |
| Q2 2026 | $20K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$260K · 12 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES12 reports
Firms it paid
| Firm | ||
|---|---|---|
| Ogr | $260K | 12 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/17for Q2 | Ogr | $20K |
| 04/19for Q1 | Ogr | $20K |
| 01/17for Q4 2025 | Ogr | $20K |
| 25/10/19for Q3 2025 | Ogr | $20K |
| 25/07/19for Q2 2025 | Ogr | $20K |
| 25/04/20for Q1 2025 | Ogr | $20K |
| 25/01/18for Q4 2024 | Ogr | $20K |
| 24/10/19for Q3 2024 | Ogr | $20K |
| 24/07/21for Q2 2024 | Ogr | $20K |
| 24/04/21for Q1 2024 | Ogr | $20K |
| 24/01/21for Q4 2023 | Ogr | $20K |
| 23/10/19for Q3 2023 | Ogr | $40K |
| 23/09/01for Q3 2023 | Ogr | Under $5,000 |